기본 정보
- 표준 SMILES
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)[O-].[Na+]- InChIKey
YDTFRJLNMPSCFM-YDALLXLXSA-M- 분자식
- C15H10I4NNaO4
- 평균 분자량
- 798.85 g/mol
- 단동위원소 질량
- 798.66864408
개요
Levothyroxine sodium anhydrous is the sodium salt of L-thyroxine. It is used as replacement therapy in the treatment of hypothyroidism. It contains a L-thyroxine(1-).
이름 및 식별자
- 우선 이름
- Levothyroxine Sodium
- IUPAC
- sodium (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate
이름 및 동의어
Levothyroxine sodiumL-Thyroxine sodium55-03-8EuthyroxUnithroidlevothroidLevoxylNovothyroxLettersynthroidThyroxine sodiumThyroxin sodium
이름 더 보기
Sodium thyroxinateThyroxine sodium salteltroxinSodium L-thyroxineThyronaminTirosintEferoxLevaxin
데이터베이스 식별자
- CAS
25416-65-3、55-03-8- PubChem CID
- 23666112
- DTXSID
DTXSID90883228- ChEMBL
CHEMBL2103741- ChEBI
CHEBI:6446- UNII
- 054I36CPMN
- EC Number
- 200-221-4、685-634-1
물성
구조 계산 물성
- 극성 표면적
- 95.6 Ų
- 수소 결합 공여자 수
- 2
- 수소 결합 수용자 수
- 5
- 회전 가능 결합 수
- 5
- 무거운 원자 수
- 25
- 형식 전하
- 0
- 복잡도
- 426
실험 및 물리화학적 성질
Human Drugs
Breast Feeding; Lactation; Milk, Human; Thyroid Hormones
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Animal DrugsFDA approved animal drugs -> Active ingredient
안전 및 규제
GHS 분류
GHS Classification
Danger
H361 (92.5%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
P203, P260, P264, P270, P280, P318, P319, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 53 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Danger
H361 (25%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
유해성 정보
Other Safety InformationIMAP assessments - L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, monosodium salt: Human health tier I assessment
Hazard Classes and Categories
Repr. 2 (92.5%)
STOT RE 1 (75%)
독성 정보
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Levothyroxine sodium
vLess-DILI-concern
3
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
화학 및 산업
약리 정보
ATC Code
H - Systemic hormonal preparations, excl. sex hormones and insulins
QH - Systemic hormonal preparations, excl. sex hormones and insulin
FDA Pharmacological Classification
LEVOTHYROXINE SODIUM
l-Thyroxine [EPC]; Thyroxine [CS]
LEVOTHYROXINE SODIUM ANHYDROUS
Thyroxine [CS]; l-Thyroxine [EPC]
용도 및 제조
UsesUse (kg) in Switzerland (2009): >5
General Manufacturing InformationL-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, sodium salt (1:1): INACTIVE
관련 반응
6건
연결된 노트
불러오는 중…